Tyrosine kinase inhibitors are de facto the more used targeted therapies for upfront treatment of metastatic renal cell carcinoma (mRCC). Among these, sunitinib and pazopanib have reported greater activity in term of progression-free survival and overall survival compared with interferon-α or placebo in two independent large phase III studies. Despite a large use in clinical practice these molecules had never been compared. The COMPARZ study recently published in the New England Journal of Medicine reports the results of a non-inferiority trial that comparing pazopanib to sunitinib as first line of therapy in mRCC patients. Here we report the activity and safety data of the study and we discuss several critical aspects related to the study design and possible confounding factors that may alter the results' interpretation.

First line treatment of metastatic renal cell carcinoma : two standards with different toxicity profile / R. Iacovelli, E. Verzoni, F. De Braud, G. Procopio. - In: CANCER BIOLOGY & THERAPY. - ISSN 1538-4047. - 15:1(2014 Jan), pp. 19-21. [10.4161/cbt.27150]

First line treatment of metastatic renal cell carcinoma : two standards with different toxicity profile

E. Verzoni;F. De Braud;
2014-01

Abstract

Tyrosine kinase inhibitors are de facto the more used targeted therapies for upfront treatment of metastatic renal cell carcinoma (mRCC). Among these, sunitinib and pazopanib have reported greater activity in term of progression-free survival and overall survival compared with interferon-α or placebo in two independent large phase III studies. Despite a large use in clinical practice these molecules had never been compared. The COMPARZ study recently published in the New England Journal of Medicine reports the results of a non-inferiority trial that comparing pazopanib to sunitinib as first line of therapy in mRCC patients. Here we report the activity and safety data of the study and we discuss several critical aspects related to the study design and possible confounding factors that may alter the results' interpretation.
First line; Non-inferiority study; Pazopanib; Phase III trial; Renal cancer; Sunitinib; Toxicity; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Pyrimidines; Pyrroles; Sulfonamides; Cancer Research; Oncology; Molecular Medicine; Pharmacology
Settore MED/06 - Oncologia Medica
CANCER BIOLOGY & THERAPY
Article (author)
File in questo prodotto:
File Dimensione Formato  
cbt.pdf

non disponibili

Tipologia: Publisher's version/PDF
Dimensione 831.17 kB
Formato Adobe PDF
831.17 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2434/426914
Citazioni
  • ???jsp.display-item.citation.pmc??? 4
  • Scopus 8
  • ???jsp.display-item.citation.isi??? 6
social impact